Shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) have been given a consensus rating of “Hold” by the nine research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $20.50.
A number of analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Keros Therapeutics in a research note on Tuesday, August 4th. Wall Street Zen downgraded Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Keros Therapeutics in a research note on Wednesday, August 12th. Zacks Research upgraded Keros Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 27th. Finally, Leerink Partners dropped their price objective on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 4th.
Check Out Our Latest Stock Analysis on KROS
Keros Therapeutics Price Performance
Keros Therapeutics (NASDAQ:KROS – Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. On average, equities analysts anticipate that Keros Therapeutics will post -5.27 EPS for the current fiscal year.
Keros Therapeutics announced that its Board of Directors has approved a stock repurchase plan on Wednesday, September 9th that authorizes the company to buyback $5.00 million in shares. This buyback authorization authorizes the company to repurchase up to 2.3% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.
Insider Buying and Selling
In other Keros Therapeutics news, insider Lorena Raquel Lerner sold 3,568 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total transaction of $36,714.72. Following the completion of the sale, the insider directly owned 27,559 shares of the company’s stock, valued at approximately $283,582.11. This represents a 11.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 5,343 shares of company stock worth $54,985 over the last ninety days. 12.60% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Keros Therapeutics
A number of large investors have recently made changes to their positions in KROS. BlackRock Inc. acquired a new position in Keros Therapeutics in the 2nd quarter worth approximately $29,898,000. Nantahala Capital Management LLC purchased a new stake in shares of Keros Therapeutics in the second quarter valued at $15,091,483. Dimensional Fund Advisors LP lifted its holdings in shares of Keros Therapeutics by 453.9% in the first quarter. Dimensional Fund Advisors LP now owns 321,360 shares of the company’s stock valued at $3,547,000 after purchasing an additional 263,347 shares in the last quarter. ADAR1 Capital Management LLC acquired a new stake in shares of Keros Therapeutics in the second quarter worth $2,641,000. Finally, Y Intercept Hong Kong Ltd grew its holdings in shares of Keros Therapeutics by 40.2% during the first quarter. Y Intercept Hong Kong Ltd now owns 164,483 shares of the company’s stock valued at $1,816,000 after buying an additional 47,122 shares in the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.
About Keros Therapeutics
Keros Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies that regulate signaling within the transforming growth factor beta (TGF-β) superfamily. These biological pathways influence blood-cell production, bone health, muscle growth and cardiovascular function, and may play a role in several serious diseases.
The company’s investigational portfolio has included elritercept (KER-050), an engineered ligand trap designed to enhance red blood cell production and address anemia associated with conditions such as myelodysplastic syndromes and myelofibrosis.
Recommended Stories
- Five stocks we like better than Keros Therapeutics
- NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can Run
- A Manufacturing Surprise Could Be a Big Win for These 2 Companies
- What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions
- 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks
Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
